Interestingly, although the most common alterations of p16 are deletions and promoter hypermethylation affecting both p16 and p14 [21,22,23], cancer-associated mutations are more commonly found in p16 than p14 [24], suggesting a critical regulatory role of p16 in the cell. Here, CDKN2A is linked to cancer.